Journal of Surgical Oncology, ISSN 0022-4790, 04/2008, Volume 97, Issue 5, pp. 479 - 479
Journal Article
Journal of Antimicrobial Chemotherapy, ISSN 0305-7453, 11/2019, Volume 74, Issue Supplement_5, pp. v2 - v4
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 06/2016, Volume 374, Issue 22, pp. 2195 - 2198
To the Editor: Zika virus (ZIKV), an emerging flavivirus, generally causes mild infection in humans but is associated with severe neurologic complications and...
MEDICINE, GENERAL & INTERNAL | CONTACT | Zika Virus - genetics | Humans | Middle Aged | Sexually Transmitted Diseases, Viral | RNA, Viral - analysis | Urine - virology | Phylogeny | Zika Virus - isolation & purification | Saliva - virology | Young Adult | Zika Virus Infection - transmission | Semen - virology | Disease Transmission, Infectious | RNA, Viral - urine | Urine | Infections | Zika virus | Disease transmission
MEDICINE, GENERAL & INTERNAL | CONTACT | Zika Virus - genetics | Humans | Middle Aged | Sexually Transmitted Diseases, Viral | RNA, Viral - analysis | Urine - virology | Phylogeny | Zika Virus - isolation & purification | Saliva - virology | Young Adult | Zika Virus Infection - transmission | Semen - virology | Disease Transmission, Infectious | RNA, Viral - urine | Urine | Infections | Zika virus | Disease transmission
Journal Article
The Lancet, ISSN 0140-6736, 09/2017, Volume 390, Issue 10101, pp. 1499 - 1510
Cabotegravir and rilpivirine are antiretroviral drugs in development as long-acting injectable formulations. The LATTE-2 study evaluated long-acting...
MEDICINE, GENERAL & INTERNAL | GSK1265744 | PHARMACOKINETICS | SAFETY | PHARMACOLOGY | ANTIRETROVIRAL THERAPY | FORMULATION | SIMPLIFICATION | BOOSTED PROTEASE INHIBITOR | HIV (Viruses) | Adults | Analysis | Health care | Antiretroviral drugs | Acquired immune deficiency syndrome--AIDS | Research & development--R&D | Human immunodeficiency virus--HIV | Clinical trials | Mutation | Disease management | Drug therapy
MEDICINE, GENERAL & INTERNAL | GSK1265744 | PHARMACOKINETICS | SAFETY | PHARMACOLOGY | ANTIRETROVIRAL THERAPY | FORMULATION | SIMPLIFICATION | BOOSTED PROTEASE INHIBITOR | HIV (Viruses) | Adults | Analysis | Health care | Antiretroviral drugs | Acquired immune deficiency syndrome--AIDS | Research & development--R&D | Human immunodeficiency virus--HIV | Clinical trials | Mutation | Disease management | Drug therapy
Journal Article
Journal of Hepatology, ISSN 0168-8278, 2017, Volume 67, Issue 3, pp. 454 - 461
Graphical abstract
Gastroenterology and Hepatology | Cirrhosis | Chronic hepatitis C | Prognosis | Mortality | End-stage liver disease | Disease progression | Hepatocellular carcinoma | Burden of disease | Natural history | Alcohol use disorders | GLOBAL BURDEN | POPULATION | VIRUS-INFECTION | RISK | LIVER FIBROSIS PROGRESSION | HCV INFECTION | HEPATOCELLULAR-CARCINOMA | EUROPEAN COUNTRIES | DISEASE | GASTROENTEROLOGY & HEPATOLOGY | Liver Transplantation | Humans | Middle Aged | Hepatitis C, Chronic - surgery | Male | Hepatitis C, Chronic - complications | Hepatitis C, Chronic - mortality | Disease Progression | Time Factors | Adult | Female | Retrospective Studies | Alcoholism - complications
Gastroenterology and Hepatology | Cirrhosis | Chronic hepatitis C | Prognosis | Mortality | End-stage liver disease | Disease progression | Hepatocellular carcinoma | Burden of disease | Natural history | Alcohol use disorders | GLOBAL BURDEN | POPULATION | VIRUS-INFECTION | RISK | LIVER FIBROSIS PROGRESSION | HCV INFECTION | HEPATOCELLULAR-CARCINOMA | EUROPEAN COUNTRIES | DISEASE | GASTROENTEROLOGY & HEPATOLOGY | Liver Transplantation | Humans | Middle Aged | Hepatitis C, Chronic - surgery | Male | Hepatitis C, Chronic - complications | Hepatitis C, Chronic - mortality | Disease Progression | Time Factors | Adult | Female | Retrospective Studies | Alcoholism - complications
Journal Article
Clinical Infectious Diseases, ISSN 1058-4838, 1/2006, Volume 42, Issue 1, pp. 57 - 62
Background. We assessed the diagnostic value of swab cultures by comparing them with corresponding cultures of percutaneous bone biopsy specimens for patients...
Osteomyelitis | Pathogens | Antibiotics | Articles and Commentaries | Diabetic foot | Foot bones | Specimens | Bones | Biopsies | Infections | Staphylococcus | INFECTIOUS DISEASES | INFECTIONS | RIFAMPIN | MICROBIOLOGY | OFLOXACIN | IMMUNOLOGY | ANTIBIOTIC-THERAPY | PATHOGENS | Diabetic Foot - complications | Foot Bones - microbiology | Humans | Middle Aged | Diabetic Foot - pathology | Foot Bones - pathology | Osteomyelitis - complications | Diabetic Foot - microbiology | Bacteria - isolation & purification | Biopsy | Osteomyelitis - microbiology | Osteomyelitis - pathology | Retrospective Studies | Case studies | Care and treatment | Diagnosis | Health aspects
Osteomyelitis | Pathogens | Antibiotics | Articles and Commentaries | Diabetic foot | Foot bones | Specimens | Bones | Biopsies | Infections | Staphylococcus | INFECTIOUS DISEASES | INFECTIONS | RIFAMPIN | MICROBIOLOGY | OFLOXACIN | IMMUNOLOGY | ANTIBIOTIC-THERAPY | PATHOGENS | Diabetic Foot - complications | Foot Bones - microbiology | Humans | Middle Aged | Diabetic Foot - pathology | Foot Bones - pathology | Osteomyelitis - complications | Diabetic Foot - microbiology | Bacteria - isolation & purification | Biopsy | Osteomyelitis - microbiology | Osteomyelitis - pathology | Retrospective Studies | Case studies | Care and treatment | Diagnosis | Health aspects
Journal Article
Gut, ISSN 0017-5749, 08/2015, Volume 64, Issue 8, pp. 1190 - 1191
[...]2011, the combination of pegylated interferon (pINF) and ribavirin (RBV) for 24 or 48 weeks was the approved treatment for chronic hepatitis C (CHC)....
COST-EFFECTIVENESS ANALYSIS | FREE REGIMENS | HEPATITIS-C VIRUS | GASTROENTEROLOGY & HEPATOLOGY | Drug Costs | Hepatitis C, Chronic - drug therapy | Health Care Costs - statistics & numerical data | Humans | Uridine Monophosphate - analogs & derivatives | Genotype & phenotype | Interferon | Sensitivity analysis | Cost analysis | Age
COST-EFFECTIVENESS ANALYSIS | FREE REGIMENS | HEPATITIS-C VIRUS | GASTROENTEROLOGY & HEPATOLOGY | Drug Costs | Hepatitis C, Chronic - drug therapy | Health Care Costs - statistics & numerical data | Humans | Uridine Monophosphate - analogs & derivatives | Genotype & phenotype | Interferon | Sensitivity analysis | Cost analysis | Age
Journal Article
Hepatology, ISSN 0270-9139, 09/2016, Volume 64, Issue 3, pp. 1004 - 1006
Journal Article
Hepatology, ISSN 0270-9139, 09/2016, Volume 64, Issue 3, pp. 1004 - 1006
Journal Article
Intensive Care Medicine, ISSN 0342-4642, 1/2015, Volume 41, Issue 1, pp. 115 - 117
Pediatrics | Pain Medicine | Emergency Medicine | Pneumology/Respiratory System | Medicine & Public Health | Intensive / Critical Care Medicine | Anesthesiology | NONHUMAN-PRIMATES | WEST-AFRICA | PROTECTION | EPIDEMIC | CRITICAL CARE MEDICINE | Fluid Therapy | Hemorrhagic Fever, Ebola - therapy | Antiviral Agents - therapeutic use | Disease Outbreaks | Humans | Immunotherapy | Hemorrhagic Fever, Ebola - epidemiology | Communicable Disease Control - organization & administration
Journal Article
Vaccine, ISSN 0264-410X, 2009, Volume 27, Issue 44, pp. 6121 - 6128
Abstract Cost-effectiveness analyses are usually not directly comparable between countries because of differences in analytical and modelling assumptions. We...
Allergy and Immunology | Rotavirus | Cost-effectiveness | Vaccination | MEDICINE, RESEARCH & EXPERIMENTAL | AUSTRALIA | EFFICACY | SAFETY | IMMUNOLOGY | GASTROENTERITIS | CHOICE | DISEASE | INFANTS | BURDEN | VACCINES | Quality-Adjusted Life Years | Rotavirus Infections - epidemiology | Cost-Benefit Analysis | Humans | Cost of Illness | Europe - epidemiology | Rotavirus Vaccines - economics | Immunity, Herd | Models, Economic | Rotavirus Infections - economics | Vaccines, Attenuated - economics | Rotavirus Infections - prevention & control | Medical care | Discount rates | Comparative analysis | Public health | Quality management | Studies | Immunization | Hospitals | Vaccines | Primary care
Allergy and Immunology | Rotavirus | Cost-effectiveness | Vaccination | MEDICINE, RESEARCH & EXPERIMENTAL | AUSTRALIA | EFFICACY | SAFETY | IMMUNOLOGY | GASTROENTERITIS | CHOICE | DISEASE | INFANTS | BURDEN | VACCINES | Quality-Adjusted Life Years | Rotavirus Infections - epidemiology | Cost-Benefit Analysis | Humans | Cost of Illness | Europe - epidemiology | Rotavirus Vaccines - economics | Immunity, Herd | Models, Economic | Rotavirus Infections - economics | Vaccines, Attenuated - economics | Rotavirus Infections - prevention & control | Medical care | Discount rates | Comparative analysis | Public health | Quality management | Studies | Immunization | Hospitals | Vaccines | Primary care
Journal Article
Diabetes Care, ISSN 0149-5992, 04/2008, Volume 31, Issue 4, pp. 637 - 642
Outcome of Diabetic Foot Osteomyelitis Treated Nonsurgically A retrospective cohort study Eric Senneville , MD 1 , Audrey Lombart , MD 1 , Eric Beltrand , MD 2...
Journal Article
Hepatology, ISSN 0270-9139, 04/2016, Volume 63, Issue 4, pp. 1090 - 1101
Hepatitis C virus (HCV) seroprevalence remains high in people who inject drug (PWID) populations, often above 60%. Highly effective direct‐acting antiviral...
ABT-450/R-OMBITASVIR | VIRUS-INFECTION | CHRONIC HCV | SOFOSBUVIR | REINFECTION | FIBROSIS PROGRESSION | PEOPLE | PREVALENCE | USERS | GASTROENTEROLOGY & HEPATOLOGY | EPIDEMIOLOGY | Prognosis | Age Factors | Hepatitis C - drug therapy | Humans | Male | Seroepidemiologic Studies | Disease Transmission, Infectious - prevention & control | Liver Cirrhosis - epidemiology | Hepatitis C - epidemiology | Sensitivity and Specificity | Female | Substance Abuse, Intravenous - complications | Hepatitis C - transmission | Models, Theoretical | Liver Cirrhosis - prevention & control | Risk Assessment | Comorbidity | Substance Abuse, Intravenous - epidemiology | Antiviral Agents - administration & dosage | Disease Progression | Hepatitis C - diagnosis | Liver Cirrhosis - virology | Primary Prevention - methods | Sex Factors | Survival Analysis | Confidence intervals | Hepatitis | Human immunodeficiency virus--HIV | Cirrhosis | Antiviral agents | Disease transmission | Liver | Fibrosis | Social organization | Hepatitis C | Morbidity
ABT-450/R-OMBITASVIR | VIRUS-INFECTION | CHRONIC HCV | SOFOSBUVIR | REINFECTION | FIBROSIS PROGRESSION | PEOPLE | PREVALENCE | USERS | GASTROENTEROLOGY & HEPATOLOGY | EPIDEMIOLOGY | Prognosis | Age Factors | Hepatitis C - drug therapy | Humans | Male | Seroepidemiologic Studies | Disease Transmission, Infectious - prevention & control | Liver Cirrhosis - epidemiology | Hepatitis C - epidemiology | Sensitivity and Specificity | Female | Substance Abuse, Intravenous - complications | Hepatitis C - transmission | Models, Theoretical | Liver Cirrhosis - prevention & control | Risk Assessment | Comorbidity | Substance Abuse, Intravenous - epidemiology | Antiviral Agents - administration & dosage | Disease Progression | Hepatitis C - diagnosis | Liver Cirrhosis - virology | Primary Prevention - methods | Sex Factors | Survival Analysis | Confidence intervals | Hepatitis | Human immunodeficiency virus--HIV | Cirrhosis | Antiviral agents | Disease transmission | Liver | Fibrosis | Social organization | Hepatitis C | Morbidity
Journal Article
Lancet, The, ISSN 0140-6736, 2016, Volume 387, Issue 10034, pp. 2183 - 2185
To link to full-text access for this article, visit this link: http://dx.doi.org/10.1016/S0140-6736(16)30059-9 Byline: Jean-Francois Delfraissy, Yazdan...
Internal Medicine | MEDICINE, GENERAL & INTERNAL | VIRUS | Communicable Diseases, Emerging - prevention & control | Global Health | Hemorrhagic Fever, Ebola - prevention & control | Humans | Emergencies | Biomedical Research - organization & administration | International Cooperation | France | Zika Virus Infection - prevention & control | Epidemics | Pandemics | Infectious diseases | Biomedical research | Collaboration
Internal Medicine | MEDICINE, GENERAL & INTERNAL | VIRUS | Communicable Diseases, Emerging - prevention & control | Global Health | Hemorrhagic Fever, Ebola - prevention & control | Humans | Emergencies | Biomedical Research - organization & administration | International Cooperation | France | Zika Virus Infection - prevention & control | Epidemics | Pandemics | Infectious diseases | Biomedical research | Collaboration
Journal Article
17.
Full Text
Reply
Hepatology, ISSN 0270-9139, 2016, Volume 64, Issue 3, pp. 1004 - 1006
Journal Article
Lancet Infectious Diseases, The, ISSN 1473-3099, 2016, Volume 16, Issue 3, pp. 294 - 294
To link to full-text access for this article, visit this link: http://dx.doi.org/10.1016/S1473-3099(16)00047-5 Byline: Marie Lachatre, Christophe Rioux, Damien...
Infectious Disease | INFECTIOUS DISEASES | COMPASSIONATE | DRUGS | OPTIMUM USE | Extensively Drug-Resistant Tuberculosis - drug therapy | Nitroimidazoles - therapeutic use | Diarylquinolines - therapeutic use | Health Services Accessibility | Humans | Male | Oxazoles - therapeutic use | Antitubercular Agents - therapeutic use | Extensively Drug-Resistant Tuberculosis - surgery | Tuberculosis
Infectious Disease | INFECTIOUS DISEASES | COMPASSIONATE | DRUGS | OPTIMUM USE | Extensively Drug-Resistant Tuberculosis - drug therapy | Nitroimidazoles - therapeutic use | Diarylquinolines - therapeutic use | Health Services Accessibility | Humans | Male | Oxazoles - therapeutic use | Antitubercular Agents - therapeutic use | Extensively Drug-Resistant Tuberculosis - surgery | Tuberculosis
Journal Article
PLoS Medicine, ISSN 1549-1277, 03/2016, Volume 13, Issue 3, p. e1001967
Ebola virus disease (EVD) is a highly lethal condition for which no specific treatment has proven efficacy. In September 2014, while the Ebola outbreak was at...
VIRAL LOAD | MEDICINE, GENERAL & INTERNAL | HEMORRHAGIC-FEVER | PATIENT | INFECTION | T-705 FAVIPIRAVIR | OUTCOMES | CONVALESCENT PLASMA | OUTBREAK | SEVERE SEPSIS | FEATURES | Antiviral Agents - therapeutic use | Guinea | Humans | Child, Preschool | Therapies, Investigational | Infant | Male | RNA, Viral - blood | Treatment Outcome | Amides - therapeutic use | Pyrazines - therapeutic use | Ebolavirus - genetics | Reverse Transcriptase Polymerase Chain Reaction | Viral Load | Feasibility Studies | Young Adult | Hemorrhagic Fever, Ebola - diagnosis | Adolescent | Adult | Female | Historically Controlled Study | Child | Hemorrhagic Fever, Ebola - drug therapy | Antiviral agents | Ebola virus infections | Drug therapy | Patient outcomes | Care and treatment | RNA | Mortality | Genomics | Clinical trials | Hostages | Biosafety | Oral medication | Ethical aspects | Non-governmental organizations | Ebola virus | Virus diseases | Analysis | Health aspects | Studies | Epidemics | Life Sciences | Social Anthropology and ethnology | Humanities and Social Sciences
VIRAL LOAD | MEDICINE, GENERAL & INTERNAL | HEMORRHAGIC-FEVER | PATIENT | INFECTION | T-705 FAVIPIRAVIR | OUTCOMES | CONVALESCENT PLASMA | OUTBREAK | SEVERE SEPSIS | FEATURES | Antiviral Agents - therapeutic use | Guinea | Humans | Child, Preschool | Therapies, Investigational | Infant | Male | RNA, Viral - blood | Treatment Outcome | Amides - therapeutic use | Pyrazines - therapeutic use | Ebolavirus - genetics | Reverse Transcriptase Polymerase Chain Reaction | Viral Load | Feasibility Studies | Young Adult | Hemorrhagic Fever, Ebola - diagnosis | Adolescent | Adult | Female | Historically Controlled Study | Child | Hemorrhagic Fever, Ebola - drug therapy | Antiviral agents | Ebola virus infections | Drug therapy | Patient outcomes | Care and treatment | RNA | Mortality | Genomics | Clinical trials | Hostages | Biosafety | Oral medication | Ethical aspects | Non-governmental organizations | Ebola virus | Virus diseases | Analysis | Health aspects | Studies | Epidemics | Life Sciences | Social Anthropology and ethnology | Humanities and Social Sciences
Journal Article